JP2015517493A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517493A5
JP2015517493A5 JP2015511470A JP2015511470A JP2015517493A5 JP 2015517493 A5 JP2015517493 A5 JP 2015517493A5 JP 2015511470 A JP2015511470 A JP 2015511470A JP 2015511470 A JP2015511470 A JP 2015511470A JP 2015517493 A5 JP2015517493 A5 JP 2015517493A5
Authority
JP
Japan
Prior art keywords
bone
subject
cell
composition
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032650 external-priority patent/WO2013169397A1/en
Publication of JP2015517493A publication Critical patent/JP2015517493A/ja
Publication of JP2015517493A5 publication Critical patent/JP2015517493A5/ja
Pending legal-status Critical Current

Links

JP2015511470A 2012-05-07 2013-03-15 新規オキシステロールアナログoxy149は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する Pending JP2015517493A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643776P 2012-05-07 2012-05-07
US61/643,776 2012-05-07
PCT/US2013/032650 WO2013169397A1 (en) 2012-05-07 2013-03-15 Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis

Publications (2)

Publication Number Publication Date
JP2015517493A JP2015517493A (ja) 2015-06-22
JP2015517493A5 true JP2015517493A5 (https=) 2016-05-26

Family

ID=49551139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511470A Pending JP2015517493A (ja) 2012-05-07 2013-03-15 新規オキシステロールアナログoxy149は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する

Country Status (10)

Country Link
US (1) US20150140059A1 (https=)
EP (1) EP2847205A4 (https=)
JP (1) JP2015517493A (https=)
KR (1) KR20150008160A (https=)
CN (1) CN104507951B (https=)
AU (1) AU2013260057A1 (https=)
CA (1) CA2872734A1 (https=)
IN (1) IN2014DN09804A (https=)
RU (1) RU2014149153A (https=)
WO (1) WO2013169397A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
CA2872751A1 (en) 2012-05-07 2013-11-14 The Regents Of The University Of California Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
JP2016517888A (ja) 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨選択的骨形成のオキシステロール骨標的薬剤
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
WO2015168636A1 (en) * 2014-05-02 2015-11-05 The Regents Of The University Of California Bone-selective osteogenic oxysterol bisphosphonate analogs
US9657052B2 (en) 2014-12-09 2017-05-23 Warsaw Orthopedic, Inc. Compounds and methods of making sterols using diols
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US12171909B2 (en) 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
US20170275330A1 (en) * 2016-03-28 2017-09-28 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US9987290B2 (en) * 2016-03-28 2018-06-05 Warsaw Orthopedic, Inc. Methods for the separation and detection of an oxysterol
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) * 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10294264B2 (en) * 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
WO2019048898A1 (en) 2017-09-05 2019-03-14 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06329697A (ja) * 1993-03-25 1994-11-29 Kowa Co 骨疾患治療剤
AU4682700A (en) * 1999-04-30 2000-11-17 Research Corporation Technologies, Inc. Bone targeting agents for osteoporosis
JP2007517041A (ja) * 2003-12-24 2007-06-28 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション 骨障害および代謝性疾患の診断、治療および予防用の化合物
CA2643732C (en) * 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
JP2010521423A (ja) * 2007-02-23 2010-06-24 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション,インコーポレーテッド 骨と相互作用するために、骨へ作用剤を標的輸送するための方法および化合物
WO2008109780A1 (en) * 2007-03-06 2008-09-12 University Of Louisville Research Foundation, Inc Methods and compounds for the targeted delivery of agents to bone for interaction therewith
CN101951915A (zh) * 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
WO2012024584A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024581A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds

Similar Documents

Publication Publication Date Title
JP2015517493A5 (https=)
JP2015518493A5 (https=)
RU2014149153A (ru) Новый аналог оксистерола, oxy149, индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез
Wang et al. The role of autophagy in bone metabolism and clinical significance
RU2014149164A (ru) Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез
Pilmane et al. Strontium and strontium ranelate: Historical review of some of their functions
Rutten et al. Low-intensity pulsed ultrasound increases bone volume, osteoid thickness and mineral apposition rate in the area of fracture healing in patients with a delayed union of the osteotomized fibula
Zhao et al. The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling
Shen et al. Pulsed electromagnetic fields stimulation affects BMD and local factor production of rats with disuse osteoporosis
JP2006503819A5 (https=)
Tao et al. Silibinin can promote bone regeneration of selenium hydrogel by reducing the oxidative stress pathway in ovariectomized rats
CA2643732A1 (en) Oxysterol compounds and the hedgehog pathway
KR20080114717A (ko) 골다공증의 치료를 위한 gsk-3 억제제
ES3041577T3 (en) Compositions comrising an opioid growth factor receptor (ogfr) antagonist for use in promoting bone formation and in the treatment of cancer.
Li et al. Selenium-modified calcium phosphate cement can accelerate bone regeneration of osteoporotic bone defect
Sheyn et al. PTH promotes allograft integration in a calvarial bone defect
Bradaschia-Correa et al. Ecto-5′-nucleotidase (CD73) regulates bone formation and remodeling during intramembranous bone repair in aging mice
Brüel et al. PTH (1–34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats
Choi et al. Betulinic acid synergically enhances BMP2-induced bone formation via stimulating Smad 1/5/8 and p38 pathways
Sritharan et al. The synergistic effects of IL-6/IL-17A promote osteogenic differentiation by improving OPG/RANKL ratio and adhesion of MC3T3-E1 cells on hydroxyapatite
Singh et al. Biological basis of distraction osteogenesis–a review
Wang et al. Effects of pulsed electromagnetic field therapy at different frequencies on bone mass and microarchitecture in osteoporotic mice
ES2701675T3 (es) Irisina para el cuidado y la prevención de la osteoporosis
Rajfer et al. Prevention of osteoporosis in the ovariectomized rat by oral administration of a nutraceutical combination that stimulates nitric oxide production
Xu et al. A personalized biomimetic dual-drug delivery system via controlled release of PTH1-34 and simvastatin for in situ osteoporotic bone regeneration